The Medicines and Healthcare products Regulatory Agency has issued a drug alert advising healthcare professionals that 16 batches of the vaccine Typhim Vi have been recalled.
A class 2 drug alert has been issued to health professionals, highlighting a problem in the manufacturing process that may have left patients with less protection than required.
The recall by Sanofi Pasteur MSD follows concerns about the effectiveness of the vaccine in some syringes distributed from 7 January 2011 due to filling problems in the manufacturing process.
As a result, some patients immunised with Typhim Vi may not be fully protected against the disease, the MHRA warned.
It has advised patients who received the vaccine, have recently returned from abroad and are unwell, to contract their general practice.
The vaccine is still available and the Department of Health is working with manufacturers to help ensure that current supply problems are resolved as soon as possible, the MHRA added.
Ian Holloway, head of the MHRA’s defective medicines report centre, said: “There are no concerns over the safety of this vaccine but the recall has taken place because the vaccine may not be as effective as it should be.
“Anyone who has been to a typhoid region of the world and has a fever, abdominal pain and vomiting should contact a healthcare professional.”